AmplifybioHorizontal WhiteV1.RGB

AmplifyBio and Vector BioMed Partner to Manufacture Plasmids and Share Capabilities that Enhance the Safety and Scalability of Lentiviral-based Gene Therapeutics

WEST JEFFERSON, Ohio, & GAITHERSBURG, Md., October 31, 2023 ( – AmplifyBio, a leading service provider for the commercialization of advanced modality therapeutics, and Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, announced a strategic partnership that aims to accelerate the development of lentiviral vector-based gene therapeutics. This collaboration brings together two industry leaders: a lentiviral vector manufacturer and an advanced therapy development organization with an integrated offering spanning discovery, optimization, preclinical safety, product characterization, product development, and manufacturing. The result of the combined capabilities is a safe and efficient one-stop solution for the development and characterization of lentiviral vector-based therapies.

As part of the agreement, AmplifyBio will become the primary plasmid manufacturer for Vector BioMed on behalf of its clients. This will allow Vector BioMed to not only access GMP (Good Manufacturing Practices) plasmid in customizable batch sizes but also seamlessly leverage AmplifyBio’s other service areas for seamless product evaluation and characterization. Furthermore, Vector BioMed clients will have access to in vitro characterization of their product as well as in vivo safety, efficacy, and toxicology assessments with pre-clinical lots of lentiviral vectors to create rapid IND-enabling data packages.

By working closely with Vector BioMed, AmplifyBio gains the support and insights of thought leaders with years of experience in the development of safe and effective Lentiviral vector-based products. The partnership supports the mission of AmplifyBio to build a multi-dimensional design and development ecosystem for the commercialization of advanced therapies. Specifically, the partnership allows AmplifyBio to align safety, efficacy, and toxicology testing with early pilot lots, allowing for full and efficient optimization early in development. The partnership further enables Vector BioMed and AmplifyBio clients to meet aggressive timelines for the development, manufacture, testing, and use of scalable and cost-effective vectors as a part of their drug substance or drug product supply chain.

“Forming these types of partnerships is critically important to AmplifyBio’s strategic vision to create a true development ‘sandbox’ environment where clients have access to technologies, expertise, and scalable manufacturing options to bring innovative drugs to market,” said J. Kelly Ganjei, CEO AmplifyBio.

“Vector BioMed, which is an industry leader in developing and manufacturing premium Lentiviral vector products, bring just that kind of resource to AmplifyBio clients pursuing that development route.” “This partnership with AmplifyBio provides our clients with end-to-end services in the development, characterization, and commercialization of lentiviral vector-based therapeutics. Our clients can leverage the expertise of two organizations that have extensive knowledge in the development and commercialization of cell and gene therapies,” said Dr Boro Dropulić, CEO of Vector BioMed.

Plasmid Manufacturing

Manufacturing at AmplifyBio

Non-viral Gene Editing

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest